Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series.

BACKGROUND

Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor.

OBJECTIVE

To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers.

METHODS

A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly).

RESULTS

All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects.

CONCLUSION

Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.